Cai Fu Zai Xian·2026-02-27 10:46Core Viewpoint - Fudan Zhangjiang has reported significant advancements in its R&D investments and clinical trials, particularly in the fields of antibody-drug conjugates (ADC) and photodynamic therapy drugs, indicating a strong potential for future growth and product diversification [1][2] Group 1: R&D Investments - The company invested approximately 358 million RMB in R&D during the reporting period, with a steady increase in the proportion of R&D spending relative to revenue [1] - R&D funding is primarily directed towards ADC and photodynamic drug development, with multiple pipelines achieving key progress [1] Group 2: ADC Developments - The Phase III clinical trial for the FDA018 ADC targeting triple-negative breast cancer has exceeded its enrollment target, with over 350 participants, and data collection is currently underway [1] - The Phase II clinical study for the FDA022 ADC, aimed at HER2 low-expressing breast cancer, has completed patient enrollment and successfully held a communication meeting with regulatory authorities [1] Group 3: Photodynamic Therapy Developments - The application for marketing authorization of the oral solution of aminolevulinic acid for intraoperative visualization in high-grade glioma has been accepted, which could enhance the company's product portfolio and core competitiveness in the photodynamic therapy sector [1] Group 4: Industrialization Support - Fudan Zhangjiang's wholly-owned subsidiary, Taizhou Fudan Zhangjiang, is providing support for the industrialization of its ADC projects, including technology transfer and production process validation [2] - The commercialization of related products is expected to create new growth points for the company, contributing to its long-term high-quality development [2]